Literature DB >> 18086673

beta-arrestin-biased agonism at the beta2-adrenergic receptor.

Matthew T Drake1, Jonathan D Violin, Erin J Whalen, James W Wisler, Sudha K Shenoy, Robert J Lefkowitz.   

Abstract

Classically, the beta 2-adrenergic receptor (beta 2AR) and other members of the seven-transmembrane receptor (7TMR) superfamily activate G protein-dependent signaling pathways in response to ligand stimulus. It has recently been discovered, however, that a number of 7TMRs, including beta 2AR, can signal via beta-arrestin-dependent pathways independent of G protein activation. It is currently unclear if among beta 2AR agonists there exist ligands that disproportionately signal via G proteins or beta-arrestins and are hence "biased." Using a variety of approaches that include highly sensitive fluorescence resonance energy transfer-based methodologies, including a novel assay for receptor internalization, we show that the majority of known beta 2AR agonists exhibit relative efficacies for beta-arrestin-associated activities (beta-arrestin membrane translocation and beta 2AR internalization) identical to the irrelative efficacies for G protein-dependent signaling (cyclic AMP generation). However, for three betaAR ligands there is a marked bias toward beta-arrestin signaling; these ligands stimulate beta-arrestin-dependent receptor activities to a much greater extent than would be expected given their efficacy for G protein-dependent activity. Structural comparison of these biased ligands reveals that all three are catecholamines containing an ethyl substitution on the alpha-carbon, a motif absent on all of the other, unbiased ligands tested. Thus, these studies demonstrate the potential for developing a novel class of 7TMR ligands with a distinct bias for beta-arrestin-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18086673     DOI: 10.1074/jbc.M708118200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  123 in total

Review 1.  Serotonin receptor signaling and regulation via β-arrestins.

Authors:  Laura M Bohn; Cullen L Schmid
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-10-07       Impact factor: 8.250

2.  Development and characterization of pepducins as Gs-biased allosteric agonists.

Authors:  Richard Carr; Yang Du; Julie Quoyer; Reynold A Panettieri; Jay M Janz; Michel Bouvier; Brian K Kobilka; Jeffrey L Benovic
Journal:  J Biol Chem       Date:  2014-11-13       Impact factor: 5.157

3.  Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling.

Authors:  Erica J Melief; Mayumi Miyatake; Michael R Bruchas; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-03       Impact factor: 11.205

Review 4.  Probing heterotrimeric G protein activation: applications to biased ligands.

Authors:  Colette Denis; Aude Saulière; Segolene Galandrin; Jean-Michel Sénard; Céline Galés
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

5.  Functional monoclonal antibody acts as a biased agonist by inducing internalization of metabotropic glutamate receptor 7.

Authors:  C Ullmer; S Zoffmann; B Bohrmann; H Matile; L Lindemann; Pj Flor; P Malherbe
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 6.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

Review 7.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

8.  {Beta}-blocker drugs mediate calcium signaling in native central nervous system neurons by {beta}-arrestin-biased agonism.

Authors:  Anastassios V Tzingounis; Mark von Zastrow; Guillermo A Yudowski
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

Review 9.  New perspectives regarding β(2) -adrenoceptor ligands in the treatment of asthma.

Authors:  J K L Walker; R B Penn; N A Hanania; B F Dickey; R A Bond
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

10.  Carboxy-terminus of CXCR7 regulates receptor localization and function.

Authors:  Paramita Ray; Laura Anne Mihalko; Nathaniel L Coggins; Pranav Moudgil; Anna Ehrlich; Kathryn E Luker; Gary D Luker
Journal:  Int J Biochem Cell Biol       Date:  2012-01-25       Impact factor: 5.085

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.